Drugmakers Sanofi and Regeneron said their experimental drug, Zaltrap, was more effective in slowing the progression of colorectal cancer than currently approved drugs, according to a report by Bloomberg Business Week.
In a trial study, Zaltrap was tested on 1,226 patients with colorectal cancer that had metastasized. All the patients had been treated with Eloxatin, an older Sanofi drug, before the trial.
Zaltrap is designed to block compounds that help tumors grow new blood vessels and are linked to inflammation. Side effects include diarrhea, fatigue, inflammation of the mucus membranes of the mouth, infections, high blood pressure, gastrointestinal pains and low white blood cell count.
Read the Bloomberg Business Week report on Zaltrap.
Related Articles on Colon Cancer:
Study: New Biopsy Needle Accurately Diagnoses Cancers of GI Tract
Study: Folic Acid May Protect Pregnant Mothers' Offspring From Colon Cancer
Office Desk Jobs Double Colon Cancer Risk